The IFIT1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphocyte cell line, offering a robust loss-of-function model for investigating IFIT1-dependent biological processes. This product comprises a heterogeneous pool of cells harboring targeted disruption of the IFIT1 gene via CRISPR/Cas9-mediated gene editing, enabling dissection of IFIT1 function without the clonal selection biases inherent in single-cell-derived lines. The polyclonal format preserves population-level diversity while abrogating IFIT1 expression, making it ideally suited for studying antiviral innate immunity, interferon signaling dynamics, and host-pathogen interactions in a T-cell context.
Jurkat cells are an extensively characterized human T lymphocyte line originally isolated from the peripheral blood of a 14-year-old male with acute T-cell leukemia. These cells retain key features of T-cell biology, including robust T-cell receptor (TCR) signaling and responsiveness to interferons, and are widely employed to model adaptive immune responses. Their well-documented signaling networks and ease of genetic manipulation establish them as a preferred host for examining the intersection of innate and adaptive immunity, particularly the role of interferon-stimulated genes in antiviral defense.
IFIT1 (Interferon-Induced protein with Tetratricopeptide repeats 1) is a pivotal interferon-stimulated gene that executes essential antiviral functions by recognizing viral RNA lacking 2′-O-methylation, thereby inhibiting viral replication. Mechanistically, IFIT1 sequesters viral RNA and disrupts translation initiation through direct interaction with the eIF3 translation initiation complex. IFIT1 transcription is potently induced by type I and II interferons via JAK1/TYK2-mediated phosphorylation of STAT1 and STAT2, which complex with IRF9 to activate interferon-stimulated response elements (ISRE). Upstream innate immune sensors such as RIG-I signal through the adaptor MAVS and kinase TBK1 to activate IRF3 and IRF7, which drive initial interferon production. IFIT1 itself interfaces with these pathways by indirectly modulating MAVS and RIG-I activity and by interacting with viral RNA and other IFIT family members IFIT2 and IFIT3, as well as viral proteins like influenza A NS1.
Deletion of IFIT1 in Jurkat cells permits focused investigation of how antiviral innate immune modules operate within a T lymphocyte environment. Jurkat cells retain intact interferon signaling machinery, expressing IFNAR1/2 and downstream STAT effectors, and thus provide a physiologically relevant backdrop to evaluate IFIT1’s contribution to interferon-mediated viral restriction. This model allows researchers to decouple IFIT1-specific effects from those of other interferon-stimulated genes and to explore its role in modulating adaptive immune cell function during viral challenge or autoimmune settings, where T-cell dysregulation is implicated.
Typical research applications include antiviral innate immunity studies, interferon signaling analysis, viral pathogenesis research, and host-pathogen interaction profiling. The polyclonal knockout cells are amenable to a variety of assays: RT-qPCR to quantify IFIT1 transcript levels, Western blotting for STAT1 phosphorylation, ISRE-luciferase reporter assays to measure interferon response, viral infection and replication assays to assess susceptibility, RNA immunoprecipitation to detect IFIT1-RNA interactions, and flow cytometry for IFIT1 protein expression. These cells serve as a versatile tool for dissecting the molecular circuitry of innate immunity in T cells. For additional details, please contact Ascent Research.
